Antimicrobial resistance (AMR) is one of the most challenging health problems faced by every country across the world. It has been estimated that the burden of deaths by antibiotic resistance may increase to 10 million each year by 2050. From a health economics perspective, patients with AMR infections use more resources for their treatment as they generally have worse clinical outcomes compared to patients with non-resistant infection. Majority of the past studies show that the healthcare cost for patients with resistant infections is higher than the care for patients with non-resistant infections because of longer duration of illness, additional diagnostic tests, longer hospital stays, need for more expensive drugs, and increased mortality. Therefore, accurate estimation of the burden of AMR is important to prevent the spread of the such resistant bacteria and allocate resources reasonably to control the AMR. Authors with this systematic review aimed to synthesize recent evidence estimating the economic burden of AMR, characterized by study perspectives, healthcare settings, study design, and income of the countries.
Link to the article: bit.ly/42pqbnM
Published On: /05/2023
